Maxim Group Reiterates “Buy” Rating for Ritter Pharmaceuticals Inc (RTTR)
Ritter Pharmaceuticals Inc (NASDAQ:RTTR)‘s stock had its “buy” rating reaffirmed by stock analysts at Maxim Group in a report issued on Monday.
Separately, Zacks Investment Research upgraded Ritter Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, September 20th.
Ritter Pharmaceuticals (NASDAQ:RTTR) traded up 10.00% during mid-day trading on Monday, reaching $1.87. The company’s stock had a trading volume of 25,927 shares. The stock’s 50 day moving average is $1.55 and its 200 day moving average is $1.53. Ritter Pharmaceuticals has a 12 month low of $0.98 and a 12 month high of $2.63. The company’s market cap is $16.05 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/17/maxim-group-reiterates-buy-rating-for-ritter-pharmaceuticals-inc-rttr.html
Ritter Pharmaceuticals (NASDAQ:RTTR) last released its quarterly earnings data on Monday, August 8th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.14. Equities research analysts predict that Ritter Pharmaceuticals will post ($1.38) EPS for the current year.
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.
Receive News & Ratings for Ritter Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.